

# Management of Complications of Prostate Cancer Treat

Ca-A Cancer Journal for Clinicians

58, 196-213

DOI: [10.3322/ca.2008.0002](https://doi.org/10.3322/ca.2008.0002)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of a Remote Proton Radiation Therapy Solution over Internet2. Telemedicine Journal and E-Health, 2009, 15, 998-1004.	2.8	4
2	Is serum calcium a biomarker of fatal prostate cancer?. Future Oncology, 2009, 5, 577-580.	2.4	17
3	Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment. Japanese Journal of Clinical Oncology, 2009, 39, 833-836.	1.3	3
4	Review: Risk stratification in the hormonal treatment of patients with prostate cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 79-94.	3.2	6
5	Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a <i>Pten</i> -Deficient Mouse Model of Prostate Cancer. Cancer Research, 2009, 69, 7466-7472.	0.9	73
6	Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis. Prostate, 2010, 70, 155-161.	2.3	10
7	Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Reviews Urology, 2009, 6, 76-85.	1.4	658
8	Exercise therapy across the prostate cancer continuum. Prostate Cancer and Prostatic Diseases, 2009, 12, 110-115.	3.9	39
9	MR Imaging of the Prostate Gland. PET Clinics, 2009, 4, 139-154.	3.0	3
10	Body Image and Quality of Life in Men With Prostate Cancer. Cancer Nursing, 2009, 32, E1-E7.	1.5	34
11	Bone Continuum of Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, S1-S7.	1.3	17
12	Genitourinary Functioning and Depressive Symptoms Over Time In Younger Versus Older Men Treated for Prostate Cancer. Annals of Behavioral Medicine, 2010, 40, 275-283.	2.9	19
13	Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu. Prostate, 2010, 70, 1395-1401.	2.3	26
14	Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer. BJU International, 2010, 106, 334-341.	2.5	10
15	Management of prostate cancer in older adults. , 0, , 186-200.		0
16	Evaluation of degarelix in the management of prostate cancer. Cancer Management and Research, 2010, 2, 39.	1.9	25
17	Estrogen receptor $\beta$ 2 and $\beta$ 5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocrine-Related Cancer, 2010, 17, 675-689.	3.1	125
18	Soy Isoflavones in Conjunction With Radiation Therapy in Patients With Prostate Cancer. Nutrition and Cancer, 2010, 62, 996-1000.	2.0	79

#	ARTICLE	IF	CITATIONS
19	A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health. <i>Endocrinology</i> , 2010, 151, 4289-4300.	2.8	72
20	Bone Continuum of Cancer. <i>Oncology Times</i> , 2010, 32, S1-S7.	0.1	0
21	Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. <i>Photodiagnosis and Photodynamic Therapy</i> , 2010, 7, 106-114.	2.6	8
22	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. <i>European Urology Supplements</i> , 2010, 9, 675-691.	0.1	19
23	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005.	27.0	3,736
25	Androgen Deprivation Therapy and Cataract Incidence Among Elderly Prostate Cancer Patients in the United States. <i>Annals of Epidemiology</i> , 2011, 21, 156-163.	1.9	10
26	Implications of Treatment on Body Image and Quality of Life. <i>Seminars in Oncology Nursing</i> , 2011, 27, 290-299.	1.5	15
27	Nerve-Highlighting Fluorescent Contrast Agents for Image-Guided Surgery. <i>Molecular Imaging</i> , 2011, 10, 7290.2010.00026.	1.4	100
28	High Perceived Stress Is Linked to Afternoon Cortisol Levels and Greater Symptom Distress in Patients With Localized Prostate Cancer. <i>Cancer Nursing</i> , 2011, 36, 470-478.	1.5	14
29	Evidence-Based Nutrition Guidelines for Cancer Survivors: Current Guidelines, Knowledge Gaps, and Future Research Directions. <i>Journal of the American Dietetic Association</i> , 2011, 111, 368-375.	1.1	54
30	Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners. <i>Quality of Life Research</i> , 2011, 20, 833-844.	3.1	94
31	The Impact of Pretreatment Prostate Volume on Severe Acute Genitourinary Toxicity in Prostate Cancer Patients Treated With Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 379-384.	0.8	31
32	Living alone, obesity and smoking: Important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. <i>Acta Oncol</i> , 2012, 51, 722-729.	1.8	47
33	Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy. <i>Prostate Cancer</i> , 2012, 2012, 1-8.	0.6	5
34	Dual-mode laparoscopic fluorescence image-guided surgery using a single camera. <i>Biomedical Optics Express</i> , 2012, 3, 1880.	2.9	29
35	Compact fluorescence and white-light imaging system for intraoperative visualization of nerves. , 2012, 8207, .		7
36	Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer. <i>Supportive Care in Cancer</i> , 2012, 20, 2287-2294.	2.2	17
37	Intraoperative Fluorescence Imaging of Peripheral and Central Nerves Through a Myelin-Selective Contrast Agent. <i>Molecular Imaging and Biology</i> , 2012, 14, 708-717.	2.6	47

#	ARTICLE	IF	CITATIONS
38	Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 596-601.	1.6	10
39	Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer. <i>Growth Hormone and IGF Research</i> , 2012, 22, 122-128.	1.1	6
40	Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. <i>Translational Oncology</i> , 2012, 5, 422-429.	3.7	26
41	Nutrition Education for Osteoporosis Prevention in Men With Prostate Cancer Initiating Androgen Deprivation Therapy. <i>Clinical Journal of Oncology Nursing</i> , 2012, 16, 497-503.	0.6	9
42	Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy. <i>Prostate</i> , 2012, 72, 1207-1213.	2.3	9
43	Exercise medicine for prostate cancer. <i>European Review of Aging and Physical Activity</i> , 2013, 10, 41-45.	2.9	7
44	The effects of multidisciplinary rehabilitation: RePCa—a randomised study among primary prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 3005-3013.	6.4	41
45	Trans-anal rectoscopic ball diathermy (TARD) for radiotherapy-induced haemorrhagic telangiectasia: a safe and effective treatment. <i>Colorectal Disease</i> , 2013, 15, 566-568.	1.4	1
46	Decrease in Lean Body Mass in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: Mechanism and Biomarkers. <i>Urology</i> , 2013, 81, 376-380.	1.0	13
47	An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of <i>TENB2</i> . <i>British Journal of Pharmacology</i> , 2013, 168, 445-457.	5.4	35
48	Androgen and Androgen Receptor-Directed Therapy as Initial Treatment for Prostate Cancer. , 2013, , 861-871.		0
50	Exercise Preferences Among Men With Prostate Cancer Receiving Androgen-Deprivation Therapy. <i>Oncology Nursing Forum</i> , 2013, 40, E358-E367.	1.2	23
51	Structure-Activity Relationship of Nerve-Highlighting Fluorophores. <i>PLoS ONE</i> , 2013, 8, e73493.	2.5	31
53	Caveolin-1 as a biomarker to predict therapeutic effect of low-frequency ultrasound combined with SonoVue on prostate cancer in nude mice model. <i>Cancer Biomarkers</i> , 2014, 14, 279-286.	1.7	1
54	Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study. <i>Aging Male</i> , 2014, 17, 87-93.	1.9	16
55	American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 225-249.	329.8	324
56	Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system. <i>Radiation Oncology</i> , 2014, 9, 118.	2.7	22
57	Recommendations for Prostate Cancer Survivorship Care: An Update to the 2009 Michigan Cancer Consortium Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae. <i>Journal of Men's Health</i> , 2014, 11, 95-107.	0.3	7

#	ARTICLE	IF	CITATIONS
58	Hypermethylation and Hypomethylation of DNA: Implication for Diagnosis and Prognosis of Prostate Cancer. OnLine Journal of Biological Sciences, 2015, 15, 83-88.	0.4	0
59	Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer. Frontiers in Oncology, 2015, 5, 151.	2.8	5
60	Botanicals: An alternative remedy to radiotherapy-induced dysuria. Complementary Therapies in Medicine, 2015, 23, 90-99.	2.7	13
61	Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. Cancer Letters, 2015, 367, 12-17.	7.2	109
62	Effects of a 15-Month Supervised Exercise Program on Physical and Psychological Outcomes in Prostate Cancer Patients Following Prostatectomy. Integrative Cancer Therapies, 2015, 14, 409-418.	2.0	32
63	Brachytherapy in pelvic malignancies: a review for radiologists. Abdominal Imaging, 2015, 40, 2645-2659.	2.0	2
64	Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen. BMC Cancer, 2016, 16, 332.	2.6	3
65	Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psycho-Oncology, 2016, 25, 282-291.	2.3	48
66	Biodegradable inflatable balloons for tissue separation. Biomaterials, 2016, 105, 109-116.	11.4	9
68	Highly-trained dogs's™ olfactory system for detecting biochemical recurrence following radical prostatectomy. Clinical Chemistry and Laboratory Medicine, 2016, 54, e67-70.	2.3	5
69	Label-free <i>in vivo</i> imaging of peripheral nerve by multispectral photoacoustic tomography. Journal of Biophotonics, 2016, 9, 124-128.	2.3	29
70	Methylation profiling identified novel differentially methylated markers including <i>OPCML</i> and <i>FLRT2</i> in prostate cancer. Epigenetics, 2016, 11, 247-258.	2.7	42
71	No obvious phenotypic abnormalities in mice lacking the Pate4 gene. Biochemical and Biophysical Research Communications, 2016, 469, 1069-1074.	2.1	3
72	700-nm Zwitterionic Near-Infrared Fluorophores for Dual-Channel Image-Guided Surgery. Molecular Imaging and Biology, 2016, 18, 52-61.	2.6	65
73	Fluorescence phenomena in nerve-labeling styryl-type dyes. Journal of Photochemistry and Photobiology A: Chemistry, 2016, 316, 104-116.	3.9	2
74	UroLift in Place of Fiducial Markers for Patients With Benign Prostatic Hyperplasia Undergoing External Beam Radiation Therapy. Urology, 2017, 104, 230-234.	1.0	13
75	10-Year Outcomes in Localized Prostate Cancer. New England Journal of Medicine, 2017, 376, 178-181.	27.0	16
76	The Artificial Urinary Sphincter: Evolution and Implementation of New Techniques in the Man with Stress Incontinence After Treatment for Prostate Cancer. Current Bladder Dysfunction Reports, 2017, 12, 159-166.	0.5	0

#	ARTICLE	IF	CITATIONS
77	Cancer survivorsâ€™™ and partnersâ€™™ key concerns and quality of life. <i>Psychology and Health</i> , 2017, 32, 1407-1427.	2.2	11
78	Intervention for patient reported urinary symptoms in prostate cancer survivors: Systematic review. <i>Journal of Cancer Survivorship</i> , 2017, 11, 643-654.	2.9	4
79	An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 1333-1339.	0.4	7
80	Predictors of recurrent hospital admissions among prostate cancer survivors. <i>Medical Oncology</i> , 2017, 34, 150.	2.5	1
81	Evolution and Management of Treatment-Related Toxicity in Anal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 91-113.	1.5	20
82	The Design of a Mobile App for Promotion of Physical Activity and Self-Management in Prostate Cancer Survivors: Personas, Feature Ideation and Low-Fidelity Prototyping. , 2017, , .		4
83	Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 378.	3.7	80
84	Apoptosis in human liver carcinoma caused by gold nanoparticles in combination with carvedilol is mediated via modulation of MAPK/Akt/mTOR pathway and EGFR/FAAD proteins. <i>International Journal of Oncology</i> , 2017, 52, 189-200.	3.3	14
85	Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 569-581.	3.1	19
86	Effect of Yikou-Sizi powder hot compress on gastrointestinal functional recovery in patients after abdominal surgery. <i>Medicine (United States)</i> , 2018, 97, e12438.	1.0	3
87	Factors associated with self-reported falls, balance or walking difficulty in older survivors of breast, colorectal, lung, or prostate cancer: Results from Surveillance, Epidemiology, and End Resultsâ€™™Medicare Health Outcomes Survey linkage. <i>PLoS ONE</i> , 2018, 13, e0208573.	2.5	21
88	Side Effects and Management of ADT for Prostate Cancer. , 2018, , 149-156.		1
89	Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer. <i>Current Urology</i> , 2018, 11, 218-224.	0.6	5
90	Oncology Rehabilitation. , 2018, , 119-147.		1
91	Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030445.	6.2	33
92	Predictors of falls in older survivors of breast and prostate cancer: A retrospective cohort study of surveillance, epidemiology and end resultsâ€™™Medicare health outcomes survey linkage. <i>Journal of Geriatric Oncology</i> , 2019, 10, 89-97.	1.0	15
94	A conceptual study on real-time adaptive radiation therapy optimization through ultra-fast beamlet control. <i>Biomedical Physics and Engineering Express</i> , 2019, 5, 055016.	1.2	2
95	Real-World Evidence of Prostatic Urethral Lift Confirms Pivotal Clinical Study Results: 2-Year Outcomes of a Retrospective Multicenter Study. <i>Journal of Endourology</i> , 2019, 33, 576-584.	2.1	34

#	ARTICLE	IF	CITATIONS
96	Cancer as a risk factor for urinary tract calculi: a retrospective cohort study using the Health Improvement Network™. Urolithiasis, 2019, 47, 541-547.	2.0	0
98	Downregulated NOX4 underlies a novel inhibitory role of microRNA-137 in prostate cancer. Journal of Cellular Biochemistry, 2019, 120, 10215-10227.	2.6	23
99	Eleutheroside E Enhances the Long-Term Memory of Radiation-Damaged <i>C. elegans</i> through G-Protein-Coupled Receptor and Neuropeptide Signaling Pathways. Journal of Natural Products, 2020, 83, 3315-3323.	3.0	15
100	Saturation transfer properties of tumour xenografts derived from prostate cancer cell lines 22Rv1 and DU145. Scientific Reports, 2020, 10, 21315.	3.3	1
101	Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells. Molecules, 2020, 25, 1320.	3.8	21
102	NONO and tumorigenesis: More than splicing. Journal of Cellular and Molecular Medicine, 2020, 24, 4368-4376.	3.6	37
103	Curcumin for the Treatment of Prostate Diseases: A Systematic Review of Controlled Clinical Trials. Advances in Experimental Medicine and Biology, 2021, 1291, 345-362.	1.6	6
104	The Use of Theory to Develop Physical Activity Interventions in Urological Cancer Survivors: A Narrative Review. Seminars in Oncology Nursing, 2021, 37, 151109.	1.5	1
105	Lower endothelium-dependent microvascular function in adult breast cancer patients receiving radiation therapy. Cardio-Oncology, 2021, 7, 18.	1.7	5
106	Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate (FACT-P (Version 4) in Prostate Cancer Patients. Journal of Cancer Education, 2021, , 1.	1.3	0
108	The introduction of wide-angle 270° laparoscopy through a novel laparoscopic camera system. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 2151-2158.	2.4	3
109	The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer. Medicine (United States), 2021, 100, e26833.	1.0	2
110	Radiation toxicity in prostate cancer patients. Medicinski Podmladak, 2021, 72, 26-33.	0.0	1
111	Physical Activity and Genitourinary Cancer Survivorship. Recent Results in Cancer Research, 2010, 186, 217-236.	1.8	15
113	Hormone Therapy for Prostate Cancer. , 2012, , 2934-2953.e7.		10
115	Prostate cancer epigenetics and its clinical implications. Asian Journal of Andrology, 2016, 18, 549.	1.6	28
116	A Pilot Clinical Trial of Radioprotective Effects of Curcumin Supplementation in Patients with Prostate Cancer. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	9
117	Sniffing out prostate cancer: a new clinical opportunity. Central European Journal of Urology, 2015, 68, 308-10.	0.3	7

#	ARTICLE	IF	CITATIONS
118	Molecular Biology Underlying the Clinical Heterogeneity of Prostate Cancer: An Update. Archives of Pathology and Laboratory Medicine, 2009, 133, 1033-1040.	2.5	44
119	Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus, 2020, 12, e8921.	0.5	23
120	Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge. Current Oncology, 2021, 28, 3918-3931.	2.2	4
121	Análisis comparativo entre los andrólogos de la LHRH de administración semestral en el tratamiento del cáncer de próstata. Archivos Espanoles De Urologia, 2010, 63, .	0.2	4
122	Atypical Small Acinar Proliferation. , 2013, , 255-268.		1
123	Androgen Ablation Therapy and Prostate Cancer: An Update. British Journal of Medicine and Medical Research, 2013, 3, 1034-1049.	0.2	1
125	Tumorerkrankungen. , 2016, , 251-303.		0
126	Evaluation of the Celecoxib Effect against Radiotherapy Induced Acute Toxicities in the Patients with Prostate Cancer Compared with Placebo Group. International Journal of Cancer Management, 2017, 10, .	0.4	0
127	Unexpected Healing of Urorectal Fistula following Radical Prostatectomy After Leuprolide Atrigel Injection. Eurasian Journal of Medicine and Oncology, 0, , .	1.0	0
128	Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. American Journal of Cancer Research, 2015, 5, 289-99.	1.4	25
129	Nerve-highlighting fluorescent contrast agents for image-guided surgery. Molecular Imaging, 2011, 10, 91-101.	1.4	62
130	Presentation, management, and outcomes of complications following prostate cancer therapy. Translational Andrology and Urology, 2014, 3, 150-5.	1.4	2
131	Prostate cancer survivorship care in the Veterans Health Administration. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2014, 31, 10-17.	0.6	7
133	Respiratory distress associated with acute hydrothorax during transurethral electrocoagulation: a case report. BMC Anesthesiology, 2022, 22, 37.	1.8	1
134	SNHG3 could promote prostate cancer progression through reducing methionine dependence of PCa cells. Cellular and Molecular Biology Letters, 2022, 27, 13.	7.0	12
135	Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1139-1145.	2.5	7
137	The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression. Molecular Cancer, 2022, 21, .	19.2	18
138	Prostate cancer screening: Continued controversies and novel biomarker advancements. Current Urology, 2022, 16, 197-206.	0.6	2



#	ARTICLE	IF	CITATIONS
140	Assessment of intrafractional prostate motion and its dosimetric impact in MRI-guided online adaptive radiotherapy with gating. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 544-553.	2.0	5
141	Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114851.	5.5	7
142	A latent class analysis of health behavior changes after cancer diagnosis among Hispanic/Latino cancer survivors. <i>Journal of Cancer Survivorship</i> , 0, , .	2.9	0
143	Rectal Cancer after Prostate Radiation: A Complex and Controversial Disease. <i>Cancers</i> , 2023, 15, 2214.	3.7	2
145	Hormones and antihormones in cancer chemotherapy. , 2023, , 589-613.		0
146	Berberamine Inhibits the Biological Activities of Prostate Cancer Cells by Modulating the ROS/NF- $\kappa$ B Axis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, .	1.7	1
147	Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches. <i>Pharmaceutics</i> , 2023, 15, 1767.	4.5	8
148	Male pediatric, adolescent, and young adult reproductive survivorship. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.5	1
149	Prostate Cancer, Treatment and Response of the Hematological System in Mexican Population. <i>International Journal of Translational Medicine</i> , 2023, 3, 286-298.	0.4	0
150	Comorbidity burden and health-related quality of life in men with advanced prostate cancer. <i>Supportive Care in Cancer</i> , 2023, 31, .	2.2	1
151	The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer. <i>Current Oncology</i> , 2023, 30, 8092-8110.	2.2	0
152	The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. <i>Communications Biology</i> , 2023, 6, .	4.4	2
153	Delayed-onset lumbosacral polyradiculitis following proton precision beam therapy for localized prostate cancer: A case report. , 2023, 2, 100281.		0
154	Triazole Moieties as Potent Drug Molecules: Synthetic Approaches and Application as Promising Candidates as Anticancer Agents (A Review). <i>Russian Journal of Bioorganic Chemistry</i> , 2023, 49, S13-S30.	1.0	0
155	Six-Month Prostate Cancer Empowerment Program (PC-PEP) Improves Urinary Function: A Randomized Trial. <i>Cancers</i> , 2024, 16, 958.	3.7	0
156	Racial and socioeconomic disparities in surgical care for post-prostate cancer treatment complications: A nationwide Medicare-based analysis. <i>BJUI Compass</i> , 0, , .	1.3	0